FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885751483> ?p ?o ?g. }

• W2885751483 endingPage "1495" @default.
• W2885751483 startingPage "1488" @default.
• W2885751483 abstract "Abstract Introduction Nonadherence to pharmacotherapies complicates studies of comparative pharmacotherapy effectiveness. Modeling adherence and abstinence simultaneously may facilitate analysis of both treatment acceptability and effectiveness. Methods Secondary analyses of a three-arm randomized comparative trial of nicotine patch, varenicline, and combination nicotine patch and lozenge among adult daily smokers (N = 1086) were conducted. Adherence rates collected via interactive voice response systems during the first 27 days of quitting were compared across treatment conditions. Repeated measures latent class analyses of adherence and abstinence in 3-day parcels through 27 days of a quit attempt were conducted with treatment, demographic, and smoking history covariates. Results Adherence varied across treatments and was lowest for nicotine lozenge use in combination nicotine replacement therapy (NRT). Five latent classes that differed significantly in 6-month abstinence rates were retained, including three subgroups of adherent participants varying in treatment response and two nonadherent groups varying in abstinence probabilities. Nonadherence was more likely among those receiving varenicline and combination NRT, relative to patch monotherapy. Varenicline and combination NRT did not promote abstinence among adherent latent classes but did promote abstinence among those partially adherent, relative to patch alone. Combination therapy attenuated increased risk of treatment disengagement with more years smoking. Minority smokers, those high in dependence, and those with shorter past abstinence were at increased risk for low-adherence and low-abstinence latent classes. Conclusions Varenicline and combination nicotine patch and lozenge are less likely to be used as directed and may not increase first-month abstinence better than patch alone when taken adherently. Implications This secondary analysis of adherence and abstinence in a comparative effectiveness trial shows that adherence is highest for the nicotine patch, next highest for varenicline, and lowest for combination nicotine patch and lozenge therapy due to low lozenge use. Distinct latent classes were found that varied in both first-month abstinence and adherence. Varenicline and combination NRT may not enhance abstinence over patch alone among smokers who take medication adherently. Adherent use of medication especially benefits those who are low in dependence and have positive quitting histories; it is less beneficial to at-risk smokers and members of racial minorities." @default.
• W2885751483 created "2018-08-22" @default.
• W2885751483 creator A5040552813 @default.
• W2885751483 creator A5077768294 @default.
• W2885751483 date "2018-08-09" @default.
• W2885751483 modified "2023-09-25" @default.
• W2885751483 title "Quitting Failure and Success With and Without Using Medication: Latent Classes of Abstinence and Adherence to Nicotine Monotherapy, Combination Therapy, and Varenicline" @default.
• W2885751483 cites W1484368424 @default.
• W2885751483 cites W1560315380 @default.
• W2885751483 cites W1581663723 @default.
• W2885751483 cites W1859891561 @default.
• W2885751483 cites W1964649651 @default.
• W2885751483 cites W1978524840 @default.
• W2885751483 cites W1980421517 @default.
• W2885751483 cites W1984116490 @default.
• W2885751483 cites W1998092626 @default.
• W2885751483 cites W2010708179 @default.
• W2885751483 cites W2011949901 @default.
• W2885751483 cites W2024588700 @default.
• W2885751483 cites W2026364558 @default.
• W2885751483 cites W2026845717 @default.
• W2885751483 cites W2057743790 @default.
• W2885751483 cites W2079817125 @default.
• W2885751483 cites W2106275478 @default.
• W2885751483 cites W2109365795 @default.
• W2885751483 cites W2112305964 @default.
• W2885751483 cites W2118061336 @default.
• W2885751483 cites W2118846274 @default.
• W2885751483 cites W2121522466 @default.
• W2885751483 cites W2123191789 @default.
• W2885751483 cites W2127608961 @default.
• W2885751483 cites W2129372385 @default.
• W2885751483 cites W2133603728 @default.
• W2885751483 cites W2141348739 @default.
• W2885751483 cites W2141810434 @default.
• W2885751483 cites W2147200107 @default.
• W2885751483 cites W2151522612 @default.
• W2885751483 cites W2157434505 @default.
• W2885751483 cites W2159009822 @default.
• W2885751483 cites W2170477339 @default.
• W2885751483 cites W2173504734 @default.
• W2885751483 cites W2271005668 @default.
• W2885751483 cites W2288746344 @default.
• W2885751483 cites W2806909877 @default.
• W2885751483 cites W4241186196 @default.
• W2885751483 cites W4294253676 @default.
• W2885751483 doi "https://doi.org/10.1093/ntr/nty157" @default.
• W2885751483 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6821172" @default.
• W2885751483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30107419" @default.
• W2885751483 hasPublicationYear "2018" @default.
• W2885751483 type Work @default.
• W2885751483 sameAs 2885751483 @default.
• W2885751483 citedByCount "8" @default.
• W2885751483 countsByYear W28857514832019 @default.
• W2885751483 countsByYear W28857514832020 @default.
• W2885751483 countsByYear W28857514832021 @default.
• W2885751483 countsByYear W28857514832023 @default.
• W2885751483 crossrefType "journal-article" @default.
• W2885751483 hasAuthorship W2885751483A5040552813 @default.
• W2885751483 hasAuthorship W2885751483A5077768294 @default.
• W2885751483 hasBestOaLocation W28857514832 @default.
• W2885751483 hasConcept C118552586 @default.
• W2885751483 hasConcept C126322002 @default.
• W2885751483 hasConcept C142724271 @default.
• W2885751483 hasConcept C168563851 @default.
• W2885751483 hasConcept C204787440 @default.
• W2885751483 hasConcept C27081682 @default.
• W2885751483 hasConcept C2776087441 @default.
• W2885751483 hasConcept C2776999253 @default.
• W2885751483 hasConcept C2777053506 @default.
• W2885751483 hasConcept C2777843972 @default.
• W2885751483 hasConcept C2779547902 @default.
• W2885751483 hasConcept C2780478649 @default.
• W2885751483 hasConcept C2780687700 @default.
• W2885751483 hasConcept C500440147 @default.
• W2885751483 hasConcept C71924100 @default.
• W2885751483 hasConceptScore W2885751483C118552586 @default.
• W2885751483 hasConceptScore W2885751483C126322002 @default.
• W2885751483 hasConceptScore W2885751483C142724271 @default.
• W2885751483 hasConceptScore W2885751483C168563851 @default.
• W2885751483 hasConceptScore W2885751483C204787440 @default.
• W2885751483 hasConceptScore W2885751483C27081682 @default.
• W2885751483 hasConceptScore W2885751483C2776087441 @default.
• W2885751483 hasConceptScore W2885751483C2776999253 @default.
• W2885751483 hasConceptScore W2885751483C2777053506 @default.
• W2885751483 hasConceptScore W2885751483C2777843972 @default.
• W2885751483 hasConceptScore W2885751483C2779547902 @default.
• W2885751483 hasConceptScore W2885751483C2780478649 @default.
• W2885751483 hasConceptScore W2885751483C2780687700 @default.
• W2885751483 hasConceptScore W2885751483C500440147 @default.
• W2885751483 hasConceptScore W2885751483C71924100 @default.
• W2885751483 hasFunder F4320332161 @default.
• W2885751483 hasFunder F4320337338 @default.
• W2885751483 hasFunder F4320337347 @default.
• W2885751483 hasIssue "11" @default.
• W2885751483 hasLocation W28857514831 @default.
• W2885751483 hasLocation W28857514832 @default.
• W2885751483 hasLocation W28857514833 @default.

• next